Abstract-In this study, we demonstrate that human umbilical cord vein-derived endothelial cells (HUVECs) expressed c-Mpl, the thrombopoietin (TPO) receptor, and that TPO activates HUVECs in vitro, as indicated by directional migration, synthesis of 1-alkyl-/1-acyl-platelet-activating factor (PAF) and interleukin- 
T he c-mpl gene encodes a member of the hematopoietic receptor superfamily that shows, in the extracellular domain, high amino acid sequence homology with the erythropoietin receptor and with the common subunit (c) of the interleukin (IL)-3, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors. 1 The identification and the cloning of the c-Mpl ligand demonstrated the involvement of c-mpl in megakaryopoiesis. 2, 3 Thus it was termed thrombopoietin (TPO). 2, 3 More recently it has been shown that TPO can directly modulate the response of mature platelets to several stimuli and thereby their homeostatic potential. 4 The in vitro and in vivo effects of TPO are mediated by the presence, on the target cells, of c-Mpl. TPO, as the other member of the hematopoietic receptor superfamily, is devoid of intrinsic tyrosine kinase activity. However, biochemical events triggered by ligand-receptor binding are characterized by tyrosine phosphorylation of multiple intracellular molecules, 5 including Janus kinase 2 (JAK2) and members of the signal transducers and activators of transcription (STAT). 6 -8 The JAKs are nontransmembrane protein tyrosine kinases that are rapidly tyrosine phosphorylated on ligand binding and play a critical signaling function for cytokine receptors. 9 One such function is the activation of STAT proteins, which are latent cytoplasmic proteins that undergo rapid tyrosine phosphorylation and dimerization following cytokine stimulation. 9 As a consequence they acquire DNA-binding activity, translocate into the nucleus, bind to specific promoter elements, and control the expression of target genes. 9 Several lines of evidence indicate that activation of the JAK/STAT signaling pathway elicits a number of responses, including changes in cell function, growth, differentiation, 9 and epithelial tubule formation. 10 Moreover, the observation that the JAK/STAT pathway regulates multiple developmental processes in Drosophila, including the formation of ectopic adult wing veins, 11 strongly suggests a role of this pathway in modulating new-vessel formation.
Although TPO has been initially defined as a lineagespecific late-acting growth factor, it has also been reported that this factor may exert effects on the erythroid and granulocytic population. 2 Indeed, the hematopoietic progenitor cells express c-Mpl, and TPO has the ability to enhance proliferation of early erythroid progenitors and directly affects erythroid differentiation. 3 Moreover, it has been recently demonstrated that TPO treatment also induces the functional activation of polymorphonuclear neutrophils. 12 These observations suggest that TPO, beyond the maturation of megakaryocytic lineage, serves a spectrum of functions. These pleiotropic effects of TPO are shared by other growth factors such as IL-3, GM-CSF, and stem cell factor, which are known to be involved in regulation of the hematopoietic tissue homeostasis. 13 It has been suggested that interaction between endothelial cells and stem cells plays a critical role in hematopoiesis during embryogenesis and possibly in adults. 14 Mammalian embryogenesis hematopoiesis is thought to begin in the yolk sac in the blood islands lined by endothelial cells. These endothelial cells are in close proximity to the developing stem cells and may provide the microenvironment required for stem cell proliferation and differentiation. 14 Several lines of evidence suggest that the endothelium of yolk sac plays a major role in the induction of hematopoiesis in the early embryo. 15 It has also been suggested that stromal cells capable of mediating hematopoiesis in fetal liver and subsequently in bone marrow have endothelial characteristics. 15 Therefore, fetal hematopoiesis parallels neoangiogenesis, which has a critical role in the development of the embryo. These observations suggest a bidirectional interaction between endothelium and hematopoietic cells, with the generation of a microenvironment favorable to the development of hematopoietic processes and, conversely, with the production of angiogenic factors by cells of hematopoietic lineage. The neoangiogenesis involves a concerted sequence of events, including directional migration and proliferation of endothelial cells and canalization of solid endothelial cords penetrating in the tissue. 16 A number of diffusible angiogenic factors have been recently characterized, including cytokines and mediators produced from the myeloid cell line. 16 Some of these angiogenic factors, such as vascular endothelial growth factor (VEGF), 17 IL-8, 18 and platelet-activating factor (PAF), 19 can also be produced by endothelial cells and possess an autocrine modulatory role on neoangiogenesis.
The aim of the present study was to evaluate whether TPO is able to induce angiogenesis. We found that human umbilical cord vein-derived endothelial cells (HUVECs) express c-Mpl and that TPO activates HUVECs in vitro, as indicated by directional migration, tubulogenesis, synthesis of PAF and IL-8, and phosphorylation of STAT1 and STAT5B. In vivo, TPO induced an angiogenic effect in a mouse model in which Matrigel was used for the delivery of mediators. These in vitro and in vivo effects of TPO were inhibited by the PAF-receptor antagonist, WEB 2170, suggesting a role of PAF as secondary mediator in TPO-induced angiogenesis.
Materials and Methods

Reagents
Matrigel was obtained from Becton Dickinson Labware. Synthetic 1-alkyl-C16 PAF (1-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) (1-alkyl-PAF) was obtained from Bachem Feinchemikalien. 1-Acyl-C16 PAF (1-palmitoyl-2-acetyl-snglyceryl-3-phosphorylcholine) (1-acyl-PAF) was obtained by acetylation of 1-palmitoyl-sn-glyceryl-3-phosphorylcholine with acetic anhydride and dimethyl-aminopyridine as previously described. 20 CV 3988, a structural analog of PAF that acts as specific PAF antagonist 21 was from Takeda Chemical Industries. WEB 2170, a triazolodiazepine (hetrazepinoic) with potent and specific PAFreceptor antagonist activity, 22 was obtained from Boehringer Ingelheim KG. Diazepam, a benzodiazepine without a significant PAF-inhibitory activity, 23 was obtained from Roche S.p.A. Antimouse T-cell serum, anti-L3/T4 and anti-Ly2 monoclonal antibodies (mAbs), anti-MAC-1 FITC-conjugated mAb, and the correspondent irrelevant isotypic IgG controls were purchased from Cedarlane. FITC-conjugated anti-rabbit IgG and anti-mouse IgG were obtained from Cappel Laboratories. Rabbit anti-human von Willebrand factor (vWF), rabbit IgG, and anti-rabbit IgG mAb (RG-96) were obtained from Sigma. Rabbit polyclonal Ab anti-basic fibroblast growth factor (bFGF) was from Immunogenex. Silica gel 60F254 thin-layer chromatography (TLC) plates were obtained from Merck. Porasil HPLC columns were provided from the Millipore chromatographic division (Waters). RPMI 1640 (GIBCO) and bovine calf serum (BCS) were from Hyclone Laboratories. Human TPO, a gift from Genzyme, was used throughout all experiments. Murine versus human TPO cDNA sequences revealed 71% sequence identity 2, 3 ; however, human TPO was active in an assay using murine megakaryocytic progenitors. 2, 3 The presence of endotoxin contamination of TPO preparation was tested by the Limulus amebocyte assay, and the concentration wasϽ0.1 ng/mL. Sepharose-protein A and phospholipase C from Bacillus cereus were purchased from Sigma Chemical Co. Nitrocellulose filters, horseradish peroxidaseconjugated protein A, molecular-weight markers, [␣-32 P]dCTP, and the chemiluminescence reagent were from Amersham. Poly(dI ⅐ dC):poly(dI ⅐ dC) was obtained from Pharmacia.
Antisera
Polyclonal anti-c-Mpl antiserum raised in rabbit immunized with a glutathione S-transferase (GST)-fusion protein containing the amino acid sequence corresponding to residues 518 to 541 (GenBank accession No. M90103) was obtained as previously described. 12 Anti-c-Mpl antiserum was affinity purified on a column of Sepharose covalently cross-linked with the GST-fusion protein. Specificity of anti-c-Mpl antiserum was assessed by competition experiments. One hundred micrograms of affinity-purified Igs were sequentially preadsorbed (twice) with 1.5 mg of GST-fusion protein covalently cross-linked with the Sepharose-protein A for 1 hour at 4°C. The recovered serum samples were used individually to immunoprecipitate platelet lysates. Polyclonal antibodies to p91 and polyclonal rabbit antiserum to the common ␤ subunit of IL-3/GM-CSF/IL-5 receptors were obtained and characterized as previously described. 24 The 4G10 and PY20 anti-phosphotyrosine antibodies were obtained from Upstate Biotechnology and from Affinity Research Products Ltd, respectively. Anti-STAT5A (L-20), anti-STAT5B (G-2), and anti-STAT5B (C-17) antisera were purchased from Santa Cruz Biotechnology, Inc.
Western Blot Analysis and Immunoprecipitation Studies
HUVEC monolayers that had been tightly confluent for a minimum of 24 hours were washed twice with PBS; serum starved for 4 hours at 37°C in endotoxin-free medium M199 containing 1% BSA, PBS (30% vol/vol), sodium orthovanadate 0.2 mmol/L, and EDTA 1 mmol/L; and incubated without or with TPO (20 ng/mL) or PAF (10 nmol/L) at 37°C for the time indicated. Protein concentration of HUVEC lysates obtained as previously described 24 was determined by the Bradford technique, and the protein content of the samples was normalized to 250 mg/sample by appropriate dilution with lysis buffer. The samples were then adsorbed by antisera coupled to Sepharose-protein A, and bound proteins were eluted and processed as previously described. 24 
Preparation of Nuclear Extract and Gel Retardation Assay
Nuclear extracts from untreated and from TPO-and PAF-treated HUVECs were prepared as described by Sadowski and Gilman. 25 The oligonucleotides used that corresponded to the prolactininducible element of the ␤-casein promoter (PIE) were G GGG GGA CTT CTT GGA ATT AAG GGA and G GGG TCC CTT AAT TCC AAG AAG TCC. 26 Those used that corresponded to the seruminducible element (SIE) of c-fos were G GGG CAT TTC CCG TAA ATC and G GGG GAT TTA CGG GAA ATG. 24 The annealed oligonucleotides were labeled by filling in the overhanging ends with Klenow fragment in the presence of [␣-
32 P]dCTP. Gel retardation reactions were performed as previously described. 24 
In Vitro PAF Synthesis by Endothelial Cells
HUVECs were prepared, grown, and characterized as described previously. 27 In standard PAF synthesis assays, HUVECs at the third or fourth passage, maintained for 24 hours in DMEM without FCS, were stimulated in 1 mL of Iscove's medium containing 0.25% BSA for various periods of time with TPO.
In Vitro Endothelial Cell Proliferation and Migration Assay
Proliferative activity of HUVECs was assayed by direct cell count as previously described. 28 Migration of HUVECs or CDC-HMEC-1 cells, kindly provided by Francisco J. Candal, was performed in Boyden's chambers as previously described. 29 Endothelial cells that passed across the polycarbonate filter after addition in the lower compartment of the chamber of vehicle alone (saline containing 0.25% BSA), PAF (10 nmol/L), or TPO (1 to 10 ng/mL) were counted at 200 magnification. The involvement of PAF-specific receptors in endothelial cell migration was evaluated by endothelial-cell treatment with 3 mol/L WEB 2170 22 or 5 mol/L CV3988, 21 which are 2 chemically unrelated specific PAF-receptor antagonists.
In vitro angiogenesis was studied on Matrigel-coated surface as described by Montesano and Orci. 30 TPO was either incorporated in Matrigel or added to the medium. To evaluate cell viability, trypan blue exclusion staining was performed at the end of the experiments.
Murine Angiogenesis Assay
Female C57 mice were used at 6 to 8 weeks of age. Matrigel (8.13 mg/mL), in liquid form at 4°C, was mixed with the experimental substances and injected (0.5 mL) into the abdominal subcutaneous tissue of mice along the peritoneal midline. 31, 32 At various times mice were killed and gels were recovered and processed for histology and immunohistochemistry as previously described. 19 Vessel area and total Matrigel area were planimetrically assessed from stained sections, as described by Kibbey et al. 33 We considered vessels only those structures possessing a patent lumen and containing red blood cells. Results were expressed as percentageϮSEM of the vessel area relative to the total Matrigel area. Animal procedures conformed to the Guide for the Care and Use of Laboratory Animals (NIH publication No. 93-23, revised 1985) .
In Vivo Experimental Protocol
The angiogenic effect of various doses of TPO (1, 5, 10, 15 , and 40 ng) in 0.5 mL of Matrigel was studied at different times and in the absence or presence of 10 U/mL heparin. In selected experiments, the effect of WEB 2170, a hetrazepinoic benzodiazepine with specific PAF-receptor antagonist activity (IC 50 ϭ0.3 mol/L on in vitro platelet aggregation), 22 on TPO-induced angiogenesis was evaluated. WEB 2170 was included in the Matrigel plug (final concentration, 250 ng/mL) and injected intraperitoneally (10 mg/kg) 30 minutes before the subcutaneous injection and daily for 6 days. Diazepam, a nonhetrazepinoic benzodiazepine with absent or minimal activity as a PAF antagonist when tested on in vitro platelet aggregation (IC 50 ϭ260 mol/L), 23 was used instead of WEB 2170 as control. To evaluate whether the angiogenic effect of TPO may depend on local production of bFGF, 10 ng/mL of anti-bFGF neutralizing antibody were added into Matrigel before injection. In preliminary experiments, this dose of antibody was found to inhibit the angiogenesis induced by 50 ng bFGF.
The direct angiogenic effect of synthetic PAF and of PAF extracted and purified from Matrigel plugs of mice challenged with TPO was also studied.
Assay and Quantification of PAF
PAF extracted and purified by the Matrigel plugs obtained from mice or from cultured HUVECs was measured by bioassay after extraction and purification by TLC and HPLC. 34 Characterization of bioactive PAF was performed by comparison with synthetic PAF according to previously described criteria. 34 To study the incorporation of radioactive precursors, 5ϫ10 5 HUVECs were incubated in 1 mL RPMI 1640 for 30 minutes with 30 mCi [ 3 H]acetate (from Amity) before stimulation. 34 Cell extracts were fractionated by TLC on aluminum-sheet silica-gel plates (silica gel 60, F254, 0.2-mm thickness; Merck) using a chloroform/methanol/acetic acid/water solvent (50:25:8:4) by volume. The plates were cut into 1-cm sections, and the radioactivity of each was measured. Radiolabeled PAF was used as a standard. To discriminate between the presence of an ester or ether group at the sn-1 position, the 1-radyl-2-[
3 H]acetylglycerols, obtained by phospholipase C treatment, were acetylated at position 3 by incubation for 16 hours at 37°C with 0.5 mL of acetic anhydride and 0.1 mL of pyridine. 35 
Immunofluorescence Study
For the study of TPO-induced STAT5B nuclear translocation, coverslip-attached HUVECs were fixed for 5 minutes in 3% paraformaldehyde in PBS (pH 7.4) containing 2% sucrose and permeabilized with HEPES-Triton X-100 buffer (20 mmol/L HEPES, pH 7.4, 300 mmol/L sucrose, 50 mmol/L NaCl, 3 mmol/L MgCl 2 , and 0.5% Triton X-100). STAT5B was detected by indirect immunofluorescence with a mouse monoclonal anti-STAT5B IgG1 (G-2; Santa Cruz) and a rabbit FITC-conjugated anti-mouse IgG as secondary antibody (Cedarlane). As control, the primary antibody was substituted by an irrelevant isotypic control mouse IgG (Cedarlane).
Results
Expression of TPO Receptor on HUVECs
To evaluate c-Mpl expression by HUVECs, cell lysates from HUVECs or platelets were immunoprecipitated with an anti-cMpl antiserum, raised against the intracellular domain of the receptor, or with a preimmune serum. The eluted proteins were subjected to 8% SDS-PAGE, and the filter was immunoblotted with the same antiserum. As shown in Figure 1A , the anti-cMpl antiserum was able to recognize TPO receptor both in platelets and in HUVECs immunoprecipitated with the anti-cMpl antiserum but not with the preimmune serum. The specificity of the anti-c-Mpl antiserum was assessed by immunoabsorption experiments. As shown in Figure 1B , after 2 steps of absorption the immunoprecipitated band corresponding to the c-Mpl protein was barely detectable.
To evaluate the specificity of TPO receptor engagement by the ligand, we studied the ability of TPO to affect the signaling pathway of other receptors similar to c-Mpl, such as the IL-3 receptor. 1 Unstimulated and TPO-or IL-3-stimulated HUVECs were immunoprecipitated with an antiserum to the ␤ signal-transducing subunit of the IL-3 receptor that is also shared by the GM-CSF and the IL-5 receptors. 5 As indicated by the antiphosphotyrosine immunoblot shown in Figure 2 , TPO, unlike IL-3, was unable to induce phosphorylation of both the IL-3 receptor ␤ subunit and the previously described phosphotyrosine-associated proteins. 24 
In Vitro Growth and Migration of HUVECs
To evaluate cell proliferation, HUVECs were stimulated every 2 days with various concentrations of TPO or with bFGF as positive control. As shown in Table 1 , TPO did not induce any significant increase in cell number, whereas bFGF stimulated cell growth. In contrast, TPO, added to the lower well of the Boyden's chamber, induced a dose-dependent migration of HUVECs across the 5-mm (pore size) gelatincoated polycarbonate filters ( Figure 3A ). The extent of migratory response observed at 10 ng/mL concentration of TPO was similar to that induced by 10 ng/mL bFGF or 10 nmol/L PAF. When TPO was also added to the upper well of the Boyden's chamber, it failed to induce a significant transmembrane migration (number of cell migrated: with 10 ng/mL TPO, 21.55Ϯ1.24; 10 nmol/L PAF, 18Ϯ3.2; and 10 ng/mL bFGF, 50.2Ϯ7.95; in unstimulated control, 17.22Ϯ6.64). Similar results were obtained using CDC-HMEC-1 microvascular human endothelial cells (data not shown). As shown in Figure 3B , heparin and polymyxin B did not affect HUVEC migration. These results indicate that the motogenic effect of TPO is independent of the synthesis of a heparin-binding growth factor and that it is not due to endotoxin contamination. Pretreatment with WEB 2170 and CV 3988, 2 structurally unrelated specific PAF-receptor antagonists, 21, 22 inhibited TPO-induced migration ( Figure  3B ). Heat-inactivated TPO did not stimulate HUVEC migration. Moreover, when HUVECs were plated on a Matrigelcoated surface, TPO induced a rapid formation of cordlike structures of endothelial cells (Figure 4 ). Cells move from their initial uniform pattern of dispersal to form a series of cell clusters joined by long, multicellular processes, previously defined as a "tube formation." 30 Cordlike structures of endothelial cells appeared within 1 hour in TPO-stimulated HUVECs ( Figure 4B) . A similar extent of cordlike structures formation was observed both in experiments in which TPO was incorporated into the Matrigel and in those in which TPO was added to the incubation medium. In untreated controls spontaneous cordlike structures of endothelial cells were absent at 1 hour ( Figure 4A ) and started to be detectable after 3 hours (data not shown). Cell viability of endothelial cells was Ͼ95% as evaluated by trypan blue exclusion assay. No Cell proliferation was assessed at the indicated times by direct cell counts of triplicate wells. The results represent the mean of 3 individual experiments.
*Number of cellsϫwellsϫ10
Ϫ4
. Cells were resuspended at 5ϫ10 4 mL in M199 with the addition of 20% BCS, seeded in 24-well plates, and allowed to adhere. After 24 hours, the medium was replaced with M199 with 15% BCS added to it, and cells were incubated for different times with or without TPO (10 ng/mL) or bFGF (10 ng/mL). changes in cell viability were observed when cells were stained before and at the end of experiments. The formation of cordlike structures of endothelial cells was an energyrequiring mechanism, as it was abrogated by 10 -2 mol/L NaN 3 , an inhibitor of the oxidative phosphorylation and glycolysis (data not shown). The ability of the microvascular human endothelial cells, CDC-HMEC-1, to form cordlike structures was also evaluated. As shown in Figure 4 , cordlike structure formation in Matrigel was present after 1 hour of TPO stimulation ( Figure 4D ), whereas it was absent in unstimulated CDC-HMEC-1 cells ( Figure 4C ).
Synthesis of PAF and IL-8 by TPO-Stimulated HUVECs
Since several cytokines were shown to induce PAF synthesis by HUVECs, the ability of TPO to stimulate the synthesis of PAF was studied. As shown in Table 2 , HUVECs synthesized PAF after stimulation with TPO in an amount comparable to that induced by tumor necrosis factor-␣ (TNF-␣) and thrombin, but with a distinct time course. PAF synthesized after TPO stimulation remained cell associated, being undetectable in the cell-free supernatant. Using radioactive acetate as a substrate for PAF synthesis, we found that PAF detected after stimulation with TPO was newly synthesized. The TLC analysis of lipid fractions extracted 30 minutes after addition of TPO to HUVECs preincubated with [ 3 H]acetate demonstrated the presence of 1 main peak of radioactivity that comigrated with synthetic [
3 H]C16-PAF. This peak was absent in the lipid fractions extracted from unstimulated HUVECs. The heterogeneity of acetylated glycerophospholipids produced by HUVECs has been extensively documented. 36 Therefore, to evaluate the molecular species of PAF produced by TPO-stimulated HUVECs, the 3 H-labeled lipids extracted and purified by TLC were modified into 1-radyl-2,3-diacetyl-glycerols as described in Materials and Methods. When the labeled 1-radyl-2,3-diacetyl-glycerols (45 500 cpm) were separated by TLC, the radioactive products appeared in 2 distinct regions of chromatogram, corresponding to the retention front of radiolabeled 1-palmitoyl-2,3-diacetylglycerol (peak I; 24 000Ϯ650 cpm) and 1-Ohexadecyl-2,3-diacetylglycerol (peak II; 15 325Ϯ720 cpm). The major radiolabeled compound produced by HUVECs was the 1-acyl derivative of PAF, which is 1000-fold less active than the alkyl derivative in terms of platelet activation. 36 The compound migrating with the 1-alkyl derivative of PAF accounted for Ϸ37% of the radiolabeled 1-radyl-2,3-diacetyl-glycerol submitted to TLC.
Moreover, we evaluate the release of IL-8 by HUVECs to investigate whether TPO was also able to stimulate the production of a polypeptide mediator. TPO induced IL-8 production by HUVECs with an early release detectable after 2 hours followed by a production that was sustained up to 24 hours ( Figure 5 ). Heat-inactivated TPO failed to induce PAF synthesis and IL-8 production.
TPO Induces STAT1 and STAT5B but Not STAT5A Tyrosine Phosphorylation in HUVECs
The involvement of the JAK/STAT pathway in TPO-induced HUVEC activation was evaluated by the analysis of STAT1, STAT5A, and STAT5B tyrosine phosphorylation. Unstimulated and TPO-stimulated HUVECs were immunoprecipitated with an anti-STAT1 antiserum and immunoblotted with an antiphosphotyrosine antibody. Kinetic analysis of STAT1 tyrosine phosphorylation, reported in Figure 6A , demonstrated that both tyrosine phosphorylation and dephosphorylation of STAT1 occurred very rapidly in TPO-stimulated HUVECs (STAT1 tyrosine phosphorylation peaked 5 minutes after TPO stimulation), suggesting a direct effect of TPO in mediating the activation of this STAT protein. When the same time-course experiments were performed using a specific antiserum to STAT5A (L-20, Santa Cruz) or STAT5B (G-2, Santa Cruz), we found that STAT5B, but not STAT5A, became tyrosine phosphorylated on TPO stimulation ( Figure  6B ). By contrast, in experiments not reported, when TPO was added to the growth factor-dependent M-07e, cells either STAT5A or STAT5B became tyrosine phosphorylated. Moreover, kinetic analysis of STAT5B activation demonstrated a delayed and persistent STAT5B tyrosine phosphorylation detectable from 30 to 90 minutes ( Figure 6B and 6C ).
TPO-Mediated STAT5B but Not STAT1 Tyrosine Phosphorylation Is Abrogated by the PAF-Receptor Antagonist WEB 2170
The delayed tyrosine phosphorylation of STAT5B observed after TPO stimulation suggested that this effect of TPO might be indirect. The finding that HUVEC activation is associated with the neosynthesis of several mediators, including PAF and IL-8, led us to evaluate the ability of the specific PAF-receptor antagonist, WEB 2170, or the IL-8 blocking antibody, to prevent TPO-mediated STAT5B tyrosine phosphorylation. Unstimulated HUVECs or HUVECs stimulated for 30 minutes with TPO, pretreated or not pretreated with WEB 2170, were immunoprecipitated with a specific antiserum to STAT5B (G-2, Santa Cruz) and immunoblotted with an anti-phosphotyrosine antibody. The results shown in Figure 7A demonstrate that tyrosine phosphorylation of STAT5B is completely abrogated by pretreatment of HUVECs with the PAF-receptor antagonist WEB 2170. The effect of WEB 2170 was specific for STAT5B, as it was unable to prevent STAT1 tyrosine phosphorylation occurring 5 minutes after TPO addition ( Figure 7B ). In contrast, the neutralizing anti-IL-8 antibody did not affect tyrosine phosphorylation of STAT5B induced by TPO (data not shown).
PAF Induces STAT5B but Not STAT5A Tyrosine Phosphorylation
The above results, demonstrating the effect of the PAFreceptor antagonist, WEB 2170, in preventing TPO-mediated STAT5B tyrosine phosphorylation, prompted us to investigate the effect of PAF on STAT5A and STAT5B activation. Unstimulated and 1-alkyl-PAF-stimulated HUVECs were immunoprecipitated with an antiserum to STAT5A (L-20, Santa Cruz) or STAT5B (G-2, Santa Cruz) and immunoblotted with an anti-phosphotyrosine antibody. The results reported in Figure 8 demonstrated that PAF induced a rapid (peaking after 5 minutes) STAT5B, but not STAT5A, tyrosine phosphorylation. We also compared the effect on STAT5B activation of 1-alkyl-PAF with that of 1-acyl-PAF. As shown in Figure 9 , when 1-acyl-PAF was used, at the same concentration of 1-alkyl-PAF, no tyrosine phosphorylation of STAT5B was detected.
TPO-and PAF-Induced Nuclear Translocation of STAT Proteins
The nuclear translocation of STAT1 and STAT5B was studied by gel retardation assay, evaluating the formation of SIE or PIE complexes in nuclear extract from untreated and TPO-or PAF-treated HUVECs. The results reported in Figure 10A demonstrated the presence of a band of SIEbinding activity that was specifically blocked by competition with unlabeled SIE, but not with the unrelated oligonucleotides corresponding to the PIE sequence. That STAT1 was present in the TPO-induced DNA-protein complex was evident from a supershift analysis in which an antibody to PAF was extracted and purified from the cell pellet (cell-associated PAF) or the supernatants (released PAF) of 15ϫ10 4 HUVECs stimulated with 10 ng/mL TPO or 10 ng/mL TNF. Unstimulated controls were always Ͻ0.1 ng/mL as cell-associated PAF and negative as released PAF. Results are expressed as meanϮSEM ng/mL PAF of 3 experiments.
STAT1, but not to STAT3, specifically caused a mobility shift of the SIE-containing complex ( Figure 10B ). These data were consistent with the inability of TPO to induce STAT3 activation (data not shown). The results reported in Figure  11A demonstrated the presence of a band of PIE-binding activity in the nuclear extracts from both TPO-and PAFtreated HUVECs that were completely blocked by adding an excess of unlabeled PIE. Supershifted experiments demonstrated that the anti-STAT5B (C-17, Santa Cruz) but not the anti-STAT5A antiserum altered the mobility shift of the PIE complex, indicating the presence of STAT5B in this complex ( Figure 11B ). As control, nuclear extracts from TPOstimulated M-07e cells were preincubated with an anti-STAT5A or an anti-STAT5B antiserum, and the results (not reported) demonstrated the presence of both proteins in the TPO-induced PIE complex.
Nuclear translocation of STAT5B was also evaluated by immunofluorescence. As shown in Figure 12A , unstimulated HUVECs showed a peripheral cytoplasmic staining for STAT5B. By contrast, a nuclear staining of STAT5B was observed after incubation both with TPO ( Figure 12B and 12C) and PAF ( Figure 12D) , with a time course that paralleled the corresponding tyrosine-phosphorylation analysis. Controls with irrelevant isotypic IgG1, used instead of the anti-STAT5B monoclonal IgG1, were negative (data not shown). Figures 13 and 14 show the results of experiments performed to evaluate the angiogenic effect of TPO in Matrigel containing 64 U/mL heparin and various concentrations of TPO, TPO plus WEB 2170, or sterile saline used as vehicle for TPO, which were injected subcutaneously into mice. The histological and morphometric analyses of Matrigel plugs were performed upon euthanizing the mice 6 days later. TPO induced a dose-dependent angiogenic response that was absent in controls containing heparin plus saline ( Figure  13A ). TPO-induced angiogenesis was significantly reduced in mice treated with Matrigel containing TPO and WEB 2170 (250 ng/mL) followed by daily intraperitoneal injection of WEB 2170 (10 mg/kg per day) ( Figure 13B ). When diazepam was used instead of WEB 2170, no significant inhibition of TPO-induced angiogenesis was observed ( Figure 13B ). In contrast, neutralizing antibody against the bFGF did not significantly reduce TPO-induced angiogenesis. In the absence of heparin, TPO induced cell migration within Matrigel but not formation of canalized vessels ( Figures 13B and 14C) . The optimal angiogenic effect of TPO required a concentration of 64 U/mL heparin. The same concentration was required for the optimal angiogenic effect of bFGF 31 or VEGF. 37 The requirement of heparin for the angiogenic effect of TPO was also indicated by the effect of protamine, which completely abrogated the angiogenesis induced by 10 ng/mL TPO ( Figure 13B ). These results suggest that the angiogenic effect of TPO depends on the production of heparin-binding growth factors. Indeed, it has been recently reported that TPO stimulates the production of VEGF. 38 The penetration into the Matrigel of cords of vWF-positive endothelial cells was observed after 6 and 24 hours of implantation of TPOcontaining Matrigel (data not shown). Canalization of vessels progressively increased in the following days and reached its , ϩ) , or 1-alkyl-PAF-treated (for 20 minutes, ϩ) HUVECs were either not treated (-) or were treated (ϩ) with 50-fold excess of unlabeled oligonucleotides (competitor) for 30 minutes before the addition of radiolabeled oligonucleotide. The complexes were then resolved by nondenaturing PAGE. The DNA-binding complex is indicated (arrow). B, The TPO-and PAF-induced complex is antigenically related to STAT5B. Nuclear extracts from TPO-treated or 1-alkyl-PAFtreated HUVECs were preincubated for 1 hour at 4°C with an antiserum to STAT5A (5A) or STAT5B (5B) before incubation with radiolabeled oligonucleotide and separated using a nondenaturing PAGE. We performed 3 individual experiments with similar results. The supershifted complex is indicated (arrow). maximum at day 6, with formation of microaneurismatic ( Figure 14A ) or linear ( Figure 14B ) structures containing red blood cells and leukocytes, which were indicative of functional vessels. Sections of the gel were stained with anti-vWF antibody to confirm the presence of endothelial cells in association with the vessels (Figure 14B, inset) . Infiltration into the Matrigel of T lymphocytes (reactive with a pan-T mAb), CD4-positive T lymphocytes (reactive with anti-L3/T4 mAb), CD8-positive T lymphocytes (reactive with anti-Ly2 mAb), and polymorphonuclear neutrophils was never observed. The staining of Matrigel sections for aspecific esterase or for Mac-1 antigen showed that monocytes were confined within the lumen of neoformed vessels but were absent within the Matrigel. As shown in Figures 13B and 14D , WEB 2170 markedly reduced the neovascularization of Matrigel induced by TPO. In Matrigel containing as control either 64 U/mL heparin alone or heparin plus heat-inactivated TPO, angiogenesis was never observed (data not shown).
In Vivo Angiogenic Effect of TPO
In some experiments Matrigel was submitted to PAF extraction at 6 hours, 24 hours, and 6 days after the beginning of the experiment. PAF was detected at 6 and 24 hours in mice injected with Matrigel containing TPO but not in controls ( Figure 15 ). When the animals were injected with Matrigel containing an amount of synthetic 1-alkyl-PAF comparable with that extracted from TPO-treated mice (5 ng/mL), an angiogenic response was observed (28Ϯ9.1 mean area percent; 5 experiments). In contrast, 1-acyl-PAF (5 ng/mL) induced a slight migration of endothelial cell into the Matrigel but not the formation of canalized vessels (5.2Ϯ1.8 mean area percent; 5 experiments).
Discussion
The aim of the present study was to evaluate whether endothelium can represent a target for TPO. The results obtained demonstrate that HUVECs express functional TPO receptors and that TPO is able to activate HUVECs in vitro and to stimulate angiogenesis in vivo via the synthesis of PAF.
The formation of new vessels involves a sequence of events including directional migration and proliferation of endothelial cells, as well as canalization of solid endothelial cords penetrating into the tissue. 16 A number of soluble factors that may act with autocrine or paracrine mechanisms have been found to modulate these events. 16 In the present study we demonstrate that TPO may engage in some of the physiological events involved in the angiogenesis. The in vitro study demonstrated that HUVECs express c-Mpl and that receptor activation by TPO promotes directional migration of HUVECs. In contrast, no proliferation was observed. Other angiogenic factors, such as TNF, were shown to promote endothelial cell motility without a direct stimulation of cell division. This suggests the involvement of secondary mediators in the full development of the angiogenic process. Indeed, it has been shown that the angiogenic effect of TNF is mediated by the production of PAF and nitric oxide. 32, 37 In the present study we observed that TPO stimulated the synthesis of PAF and of IL-8. Despite the fact that both of these mediators possess angiogenic properties, the experi- . Unstimulated HUVECs showed a peripheral cytoplasmic staining, whereas nuclear staining of STAT5B started to be detectable after 20 minutes and was maximal after 40 minutes of incubation with TPO. In contrast, nuclear staining of STAT5B was already detectable after 20 minutes of incubation with 1-alkyl-PAF. Magnification, ϫ600. Figure 13 . Angiogenic effect of TPO in vivo. Matrigel containing 10 U/mL heparin was mixed with various doses of TPO (1 to 40 ng/mL) or with vehicle alone (control) and was injected subcutaneously into mice (A). After 6 days mice were killed, and the Matrigel plugs were excised and processed for light and immunofluorescence microscopy. Quantitation of neovascularization was performed on hematoxylin-eosin-stained histological sections as described in Materials and Methods, and results were expressed as percentageϮSEM of the vessel area to the total Matrigel area. Each individual experimental group included 10 mice. ANOVA with Newman-Keuls test was performed. *PϽ0.05, control vs 1, 5, 15, or 40 ng/mL TPO. B, Effect of TPO alone (15 ng/mL) or in the presence of heparin (64 U/mL), heparin plus protamine (ϩprotamine, 50 mg/mL), WEB 2170, diazepam; or anti-FGF antibody (10 mg/mL). WEB 2170 (final concentration, 250 ng/mL) or diazepam (final concentration, 15 g/mL) was included in the Matrigel plug and injected intraperitoneally (WEB 2170: 10 mg/kg; diazepam: 0.5 mg/kg) 30 minutes before the subcutaneous injection and daily for 6 days. Anti-bFGF neutralizing antibody was included in Matrigel before injection.
ments with the PAF-receptor antagonists and with anti-IL-8 blocking antibody indicate that the directional migration elicited in vitro by TPO was mainly PAF dependent. Several studies demonstrated that HUVECs can synthesize various molecular species of PAF with different biological properties. 36 PAF synthesized after TPO stimulation contained Ϸ63% and Ϸ37% of 1-acyl-PAF and 1-alkyl-PAF, respectively. The study of the angiogenic potential of these PAF analogues suggests that the 1-alkyl derivative of PAF mainly accounts for the angiogenic activity observed in vivo.
The activation of HUVECs by TPO was also supported by biochemical studies indicating the involvement of STAT proteins. The STAT are cytosolic transcriptional factors that are tyrosine phosphorylated following ligand stimulation. 9 They form homo-or heterodimers and translocate into the nucleus, where they bind and activate specific DNA sequences. 9 Several lines of evidence indicate that TPO treatment both in proliferating cells and in terminally differentiated elements, such as platelets and neutrophils, leads to the activation of the STAT signaling pathway. 6, 8 Among the STAT proteins STAT1, STAT3, and STAT5 seem to be strictly related to TPO-mediated receptor activation. 6 -8 Our results demonstrate a rapid and transient tyrosine phosphorylation of STAT1 with a consequent formation of an SIE complex on TPO treatment. Unlike other STAT proteins, STAT5 consists of 2 proteins, which are referred to as STAT5A and STAT5B. 9,39 These 2 proteins are encoded from 2 distinct yet highly homologous genes and can be differently activated by a wide range of cytokines. 9 We found that TPO-mediated HUVEC activation is associated with STAT5B but not with STAT5A tyrosine phosphorylation. These data are consistent with the observed nuclear translocation of STAT5B and with the formation of a PIE complex containing STAT5B only. Similar patterns of STAT activation are triggered by a number of cytokine receptors sharing structural features with c-Mpl, including erythropoietin, GM-CSF, IL-3, and IL-5 receptors. 1 Moreover, it has been recently reported that activation of c-Mpl in an erythroleukemia cell line may affect the signaling pathway of the GM-CSF/IL-3/IL-5 receptors via the phosphorylation of their common ␤ subunit. 40 However, our finding that TPO was unable to activate the signaling through the common ␤ subunit suggests that STAT5 activation as well as the biological response of HUVECs to TPO is specifically triggered by TPO receptor engagement.
The activation of STAT5B was delayed and temporarily correlated with the synthesis of PAF induced by TPO. Moreover, the PAF-receptor inhibitor WEB 2170 was shown to prevent STAT5B activation but not STAT1 activation. These observations, together with the finding that 1-alkyl-PAF, but not 1-acyl-PAF, induced a rapid STAT5B tyrosine phosphorylation with subsequent translocation into the nucleus, suggest that TPO-induced STAT5B activation is secondary to the production of the alkyl derivative of PAF. Despite the absence of direct evidence for a role of STAT5B in mediating the angiogenesis induced by TPO, the observed correlation between the activation of STAT5B and the production of the angiogenic derivative of PAF suggests a potential role of the STAT pathway in the formation of new vessels. Indeed, it has been found that the JAK/STAT pathway is involved in the formation of ectopic adult wing veins in Drosophila. 11 When TPO-containing Matrigel was injected subcutaneously in mice, a dose-dependent neoangiogenesis was observed. However, for the full expression of in vivo angiogenic properties, the bioactivity of PAF was required. Indeed, WEB 2170 significantly prevented TPO-but not bFGF-induced angiogenesis. Moreover, we observed that the TPO-induced angiogenesis was associated with the synthesis of PAF within the Matrigel. This study does not provide direct evidence of a cellular source of PAF produced within Matrigel after TPO stimulation; however, endothelial cells were the predominant cell population detectable at 6 and 24 hours, when PAF was synthesized within the Matrigel.
PAF is a phospholipid mediator with multiple biological activities relevant for the development of several pathological and physiological processes, such as inflammation, shock, embryogenesis, and cell differentiation. 36, 41 It has recently been shown that PAF directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparindependent mechanism. 19, 42 PAF acts, on endothelial cells, through a specific receptor, 19, 43 which belongs to the family of "serpentine" receptors containing 7 ␣-helical domains that weave in and out of the plasma membrane. 43 Specific antagonists of PAF receptor have been synthesized and are currently used in studies of the pathophysiology of PAF. 41 Several lines of evidence indicate that PAF acts as secondary mediator of angiogenesis induced by TNF and hepatocyte growth factor, as PAF is actively synthesized in vivo during the angiogenic processes and a PAF-receptor antagonist significantly reduced the angiogenic response to these cytokines. 32 , 44 The present observation that PAF is synthesized by HUVECs stimulated in vitro with TPO and in vivo within Matrigel during TPO-induced neoangiogenesis, as well as the observation that a specific PAF-receptor antagonist, WEB 2170, inhibits in vitro HUVEC migration and, in vivo, the angiogenic process, suggests that this phospholipid acts as a secondary mediator also for TPO. PAF may act as a mediator of cell-to-cell communication involved in the amplification of the signal triggered by TPO by determining the production of other endothelial-derived heparin-dependent angiogenic factors that may account for the in vivo endothelial cell proliferation. Indeed, PAF has been shown to induce the expression within Matrigel of several angiogenic factors, including VEGF and its specific receptor flk-1. 45 On the other hand, it has been recently shown that TPO triggers the production of VEGF in c-Mpl-expressing cells. 38 Therefore, one can speculate that PAF may stimulate migration of endothelial cells while VEGF may provide the signal for cell proliferation. Further studies are needed to investigate the pathophysiological role of TPO in angiogenesis. The observation that fetal hematopoiesis parallels neoangiogenesis suggests a bidirectional interaction between endothelial and hematopoietic cells. In this context, TPO may contribute to generate a microenvironment favorable to a coordinated development of hematopoiesis and angiogenesis.
In conclusion, the results of the present study indicate that TPO is able to activate endothelial cells and to induce an angiogenic response that is mediated by the synthesis of PAF. Moreover, biochemical analysis supports the hypothesis that STAT5B may be involved in the signaling pathway leading to PAF-dependent angiogenesis. The failure to demonstrate a defect in vasculogenesis/angiogenesis by targeted inactivation of either c-mpl 3 or STAT5B 46 genes may be explained by the redundancy of angiogenic mechanisms acting in vivo. To further investigate the role of STAT5B-dependent signaling pathway in vasculogenesis and neoangiogenesis, generation of transgenic mice with a specific endothelial promoter containing a dominant negative STAT5B construct, is under development in our laboratory. 
